ENTRY       D10354                      Drug
NAME        Dupilumab (USAN/INN);
            Dupilumab (genetical recombination) (JAN);
            Dupixent (TN)
PRODUCT     DUPIXENT (sanofi-aventis U.S. LLC)
FORMULA     C6512H10066N1730O2052S46
EXACT_MASS  146806.3649
MOL_WEIGHT  146896.9522
SEQUENCE    (Heavy chain)
            EVQLVESGGG LEQPGGSLRL SCAGSGFTFR DYAMTWVRQA PGKGLEWVSS ISGSGGNTYY
            ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDR LSITIRPRYY GLDVWGQGTT
            VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
            VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEFL
            GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ
            FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE PQVYTLPPSQ
            EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSRLTVDKS
            RWQEGNVFSC SVMHEALHNH YTQKSLSLSL G
            (Light chain)
            DIVMTQSPLS LPVTPGEPAS ISCRSSQSLL YSIGYNYLDW YLQKSGQSPQ LLIYLGSNRA
            SGVPDRFSGS GSGTDFTLKI SRVEAEDVGF YYCMQALQTP YTFGQGTKLE IKRTVAAPSV
            FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
            SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
            (Disulfide bridge: H22-H96, H139-L219, H152-H208, H231-H'231, H234-H'234, H266-H326, H372-H430, H'22-H'96, H'139-L'219, H'152-H'208, H'266-H'326, H'372-H'430, L23-L93, L139-L199, L'23-L'93, L'139-L'199)
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
            Dermatological agent
             DG03243  Atopic dermatitis agent
REMARK      Therapeutic category: 4490
            ATC code: D11AH05
            Product: D10354<JP/US>
EFFICACY    Anti-inflammatory, Anti-IL-4/IL-13 antibody
  DISEASE   Atopic dermatitis [DS:H01358]
            Asthma [DS:H00079]
  TYPE      Monoclonal antibody
TARGET      IL4R (CD124) [HSA:3566] [KO:K05071]
  PATHWAY   hsa04060(3566)  Cytokine-cytokine receptor interaction
            hsa04151(3566)  PI3K-Akt signaling pathway
            hsa04630(3566)  JAK-STAT signaling pathway
            hsa04640(3566)  Hematopoietic cell lineage
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             D DERMATOLOGICALS
              D11 OTHER DERMATOLOGICAL PREPARATIONS
               D11A OTHER DERMATOLOGICAL PREPARATIONS
                D11AH Agents for dermatitis, excluding corticosteroids
                 D11AH05 Dupilumab
                  D10354  Dupilumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Interleukin Blockers
                Dupilumab
                 D10354  Dupilumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              44  Allergic agents
               449  Miscellaneous
                4490  Miscellaneous
                 D10354  Dupilumab (USAN/INN); Dupilumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D10354  Dupilumab
             Dermatological agent
              DG03243  Atopic dermatitis agent
               D10354  Dupilumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D10354  Dupilumab
             Dermatological agent
              DG03243  Atopic dermatitis agent
               D10354  Dupilumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Interleukin receptors
                IL4R (CD124)
                 D10354  Dupilumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10354
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10354
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10354
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10354
DBLINKS     CAS: 1190264-60-8
            PubChem: 172232447
///
